Akili Interactive Labs

What Akili Interactive Labs does

Akili Interactive Labs, founded in 2011 and headquartered in Boston, is a digital therapeutics company that develops software-based cognitive treatments delivered through action video game experiences. The company's flagship product, EndeavorRx, received FDA De Novo authorization in June 2020 as the first prescription video game treatment, indicated to improve attention function in children ages 8-12 with primarily inattentive or combined-type ADHD. In June 2024, Akili received FDA authorization for EndeavorOTC, the first over-the-counter video game-based therapy for adult ADHD. Both products are powered by Akili's proprietary Selective Stimulus Management Engine (SSME), which presents specific sensory stimuli paired with simultaneous motor challenges designed to target neural systems involved in attentional control, using adaptive closed-loop algorithms that personalize treatment difficulty in real time. The company also maintains two additional technology platforms in its pipeline — Body Brain Trainer (BBT) and Spatial Navigation Engine (SNAV) — targeting fronto-parieto-cerebellar and hippocampal neural systems respectively. Akili distributes EndeavorRx exclusively through licensed healthcare provider prescriptions and EndeavorOTC directly to consumers via the Apple App Store and Google Play; the company also holds a CE Mark for Europe and licensing agreements with Shionogi (Japan) and TALi for international markets. Following a SPAC business combination in August 2022 that raised over $163 million, Akili was delisted and acquired by Virtual Therapeutics in July 2024 for approximately $34 million, with 88.2% of shares tendered in the transaction.

Name

Akili Interactive Labs

Legal name

Akili Interactive Labs, Inc.

Website

https://akiliinteractive.com

Company type

Public

Founded year

2011

Operating status

Acquired

Headcount range

51–100 employees

Short description

Akili Interactive Labs is a Boston-based digital therapeutics company that develops FDA-authorized video game-based cognitive treatments, including prescription EndeavorRx for children with ADHD and over-the-counter EndeavorOTC for adults with ADHD, powered by its proprietary adaptive SSME technology platform.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Pediatrics & Adolescent Therapeutics (Digital) (HLACANAL)

akta.pro secondary industry

Executive Functioning & Behavioral Support Tools (ADHD, SEL/Behavior Tracking, Routines) (EDAFAKAG)

Keywords

• Digital therapeutics
• Prescription video game therapy
• ADHD cognitive treatment
• FDA-authorized digital medicine
• Neurological cognitive interventions

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Prescription Digital Therapeutic Sales (EndeavorRx): EndeavorRx is available by prescription only through licensed healthcare providers. Revenue generated from prescription digital therapeutic sales for pediatric ADHD treatment.
2. Over-the-Counter Digital Therapeutic Sales (EndeavorOTC): EndeavorOTC is sold directly to consumers through app stores (Apple App Store and Google Play) without prescription for adult ADHD treatment.

Pricing tiers

Distribution channels3 records

Marketing channels6 records

Core offering

Akili Interactive Labs develops FDA-authorized digital therapeutics delivered as video game experiences for the treatment of attention deficit hyperactivity disorder (ADHD). The company sells EndeavorRx, a prescription-only video game treatment for children ages 8-12 with primarily inattentive or combined-type ADHD, and EndeavorOTC, an over-the-counter game-based treatment for adults with ADHD. Both products are powered by the company's proprietary Selective Stimulus Management Engine (SSME) technology that uses adaptive algorithms to target neural systems involved in attentional control.

Product overview

Akili Interactive Labs develops a portfolio of digital therapeutics delivered as video game experiences. The company offers two consumer-facing products: EndeavorRx (FDA-authorized prescription treatment for children ages 8-12 with ADHD) and EndeavorOTC (FDA-authorized over-the-counter treatment for adults with ADHD). Both products are powered by Akili's proprietary Selective Stimulus Management Engine (SSME) technology that uses adaptive closed-loop algorithms to automatically adjust difficulty and personalize treatment. The company also maintains additional technology platforms including Body Brain Trainer (BBT) and Spatial Navigation Engine (SNAV) in its development pipeline for cognitive impairments across multiple neurological and psychiatric conditions.

Differentiator

Problem solved

Functional benefit

Brands

• EndeavorRx: FDA-authorized prescription video game treatment for children with ADHD ages 8-12
• EndeavorOTC

Products and services

• EndeavorRx FDA-authorized prescription video game treatment indicated to improve attention function in children ages 8-12 with primarily inattentive or combined-type ADHD. Delivered as an engaging action video game experience using proprietary SSME technology with adaptive difficulty algorithms. Available only through a licensed healthcare provider prescription. Received Conformité Européenne (CE) Mark certification for Europe.
• EndeavorOTC FDA-authorized over-the-counter game-based treatment clinically proven to improve focus and attention in adults with ADHD, available without prescription. Uses the same proprietary SSME technology as EndeavorRx, adapted for adult users. Distributed through Apple App Store and Google Play.

Quantifiable outcome

• Statistically significant improvement in TOVA-ACS attention scores (p<0.0001) in adolescents after 4 weeks of treatment
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• RobloxminorStrategic or Co-development Partner · 26 May 2022Integration of prescription video game treatment (EndeavorRx) with Roblox virtual world platform, announced May 26, 2022. Represents strategic move to expand engagement through virtual world experiences.
• ShionogicoreStrategic or Co-development Partner · 29 September 2021Strategic licensing agreement for Japan market. Phase 2 study in Japan showed Akili's digital treatment was well-received and improved inattention symptoms in children with ADHD.
• TALiminorStrategic or Co-development Partner · 17 August 2021Strategic licensing agreement extending Akili portfolio and industry leadership in prescription digital therapeutics for cognitive impairments.
• Weill Cornell MedicinecoreStrategic or Co-development Partner · 7 April 2021Collaborative research partnership to study digital therapeutic AKL-T01 as treatment for COVID brain fog. Led by Dr. Faith Gunning and Dr. Abhishek Jaywant from Weill Cornell Medicine.
• NewYork-Presbyterian HospitalcoreStrategic or Co-development Partner · 7 April 2021Collaborative research partnership studying AKL-T01 digital therapeutic for COVID brain fog treatment. Part of academic collaboration for cognitive rehabilitation research.
• Vanderbilt University Medical CentercoreStrategic or Co-development Partner · 7 April 2021Academic research partnership led by Dr. James Jackson, Assistant Director of The ICU Recovery Center. Collaboration to study digital therapeutic for COVID brain fog in survivors.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Click Therapeutics: Click Therapeutics develops prescription digital therapeutics across multiple indications (depression, migraine, smoking cessation) using similar FDA-authorization pathway and adaptive software platform approach as Akili, making it a direct competitor in the DTx commercial landscape.
• Pear Therapeutics: Pear Therapeutics was the pioneering prescription digital therapeutics company (reSET, reSET-O, Somryst) before filing for bankruptcy in 2023—a direct historical peer to Akili in FDA-authorized software-based therapeutics targeting CNS conditions, and serves as a cautionary comparable for the commercial challenges DTx companies face.
• Big Health: Big Health develops FDA-cleared digital therapeutics for insomnia (Sleepio) and anxiety (Daylight), sharing Akili's model of clinically validated, software-delivered behavioral interventions for mental health conditions with similar payer/provider commercialization approaches.
• Mahana Therapeutics: Mahana Therapeutics develops prescription digital therapeutics for conditions including IBS and tinnitus, sharing Akili's model of FDA-authorized software therapeutics with payer/provider distribution—though targeting gastroenterology and ENT rather than neuro/psych conditions.

Emerging players

• Cerebral: Cerebral is a telehealth platform specifically focused on ADHD (alongside anxiety and depression) that diagnoses and prescribes stimulant medication directly to consumers—targeting the same adult ADHD patient pool as EndeavorOTC but via a medication-first rather than software-first model.
• Done. Done (Done First) is an ADHD-focused telehealth company offering diagnosis and prescription stimulant treatment to adults—competing for the same adult ADHD demand that EndeavorOTC targets, with a complementary medication-based rather than digital therapeutic approach.
• Woebot Health: Woebot Health develops AI-powered chatbot-based digital therapeutics for mental health conditions including depression and anxiety—sharing Akili's vision of software-delivered mental health interventions but using conversational AI rather than video game mechanics as the engagement modality.

Broad incumbents

• Headspace Health: Headspace Health (merged with Ginger) offers digital mental health including therapy and self-guided tools for ADHD, anxiety, and depression—broader mental health incumbent with subscription consumer and B2B employer channels that compete for the same consumer attention/wellness spend as EndeavorOTC.
• BetterHelp: BetterHelp is the largest online therapy platform offering subscription-based access to licensed therapists for ADHD, anxiety, and depression—a broad incumbent in digital mental health that competes for the same consumer mental health wallet share as EndeavorOTC, though via human-delivered rather than software-delivered therapy.
• Omada Health: Omada Health is a long-established digital therapeutics company targeting diabetes prevention, hypertension, and musculoskeletal conditions with a similar employer/payer channel model to Akili's prescription DTx approach, though focused on cardiometabolic rather than neuro/psych conditions.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/akili-interactive
• Xx.com/akililabs

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds8 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akili Interactive Labs